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Abstract 
Lactate has been shown to offer neuroprotection in several pathological conditions. This beneficial 
effect has been attributed to its use as an alternative energy substrate. However, recent 
description of the expression of the HCA1 receptor for lactate in the central nervous system calls 
for reassessment of the mechanism by which lactate exerts its neuroprotective effects. Here we 
show that HCA1 receptor expression is enhanced twenty-four hours after reperfusion in an MCAO 
stroke model, in the ischemic cortex. Interestingly, intravenous injection of L-lactate at reperfusion 
led to further enhancement of HCA1 receptor expression in the cortex and striatum. Using an in 
vitro oxygen-glucose deprivation model we show that the HCA1 receptor agonist 3,5-
dihydroxybenzoic acid reduces cell death. We also observed that D-lactate, a reputedly non-
metabolizable substrate but partial HCA1 receptor agonist also provided neuroprotection in both 
in vitro and in vivo ischemia models. Quite unexpectedly, we show D-lactate to be partly extracted 
and oxidized by the rodent brain. Finally, pyruvate offered neuroprotection in vitro while acetate 
was ineffective. Our data suggest that L- and D-lactate offer neuroprotection in ischemia most 
likely by acting as both an HCA1 receptor agonist for non-astrocytic (most likely neuronal) cells as 
well as an energy substrate.  
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Introduction 
Stroke is a frequent and often disabling disease whose early identification and treatment within a 
few hours from symptom onset are essential. In ischemic stroke, the most common stroke subtype 
resulting from an arterial occlusion, energy failure due to lack of oxygen and glucose supply to the 
brain is the central mechanism leading to neural damage. Brain metabolism therefore plays a 
critical role in the pathophysiological mechanisms underlying neuronal damage in stroke and for 
recovery. Even though glucose is known as the brain energy substrate par excellence, other 
metabolic intermediates such as monocarboxylates including lactate, pyruvate, acetate and 
ketone bodies have been shown to be oxidized for energy production (1-3) under certain 
conditions. Brain energy metabolism is a compartmentalized process involving neurons as well as 
astrocytes and oligodendrocytes, with metabolic interactions between different cell types. 
Monocarboxylates can be transported to and from different cell types by monocarboxylate 
transporters (MCTs) with different degrees of affinity. MCTs are a family of proton-dependent 
carriers where MCT1, MCT2 and MCT4 are the main MCTs in the central nervous system. Under 
physiological conditions, MCT1 is expressed in endothelial cells, astrocytes and oligodendrocytes, 
MCT4 in astrocytes and MCT2 is the main transporter in neurons. Under hypoxic conditions, MCT1 
and MCT2 are also expressed in activated microglia (4-6).  
Beside its role as an energy substrate, lactate also acts as a signaling molecule via the HCA1 
receptor in adipose tissue and skeletal muscle (7). Interestingly, recent work revealed the 
presence of the HCA1 receptor in different brain structures, including cortex, hippocampus and 
cerebellum (8) and it has been shown that lactate administration to cortical neurons induced 
specific modulations in calcium transients frequencies in the same manner as a specific HCA1 
receptor agonist (9). HCA1 receptor involvement has also been suggested in neurological disorders 
such as cerebral malaria (10).  
We have previously shown that L-lactate administration is neuroprotective in models of cerebral 
ischemia both in vitro and in vivo: it attenuated neuronal death in vitro in organotypic 
hippocampal slice cultures subjected to oxygen and glucose deprivation (11). Both, 
intracerebroventricular and intravenous administration of L-lactate after transient middle cerebral 
artery occlusion (tMCAO) lead to a reduction in lesion size and improved neurological outcome 
(11, 12). While it was assumed so far that lactate exerts its neuroprotective effect by acting as a 
metabolic substrate for energy-deprived neurons, the mode of action is so far not characterized 
and recent data on the presence and role of the lactate receptor HCA1 in the CNS challenges this 
assumption. In the present study, we have explored both possible modes of action, as a metabolic 
substrate and signaling molecule. Understanding the mechanisms by which lactate exerts its 
neuroprotective effect is essential in order to adequately translate this promising preclinical 
neuroprotection strategy to a clinical setting. 
 
 
Materials and methods 
All experiments were conducted in accordance with ordinance 455.163 of the Swiss Federal 
Veterinary Office and approved by the Service Cantonal des Affaires Vétérinaires (license number 
VD2017.4b to LH) and the Kanton Zürich Gesundheitsdirektion Veterinäramt (license number 
ZH53/2007 to BW) (cantonal veterinary authority). 
Transient middle cerebral artery occlusion in the mouse 
A total of 55 male CD1 mice (body weight 26-35 g, Charles River, L’arbresle, France) were housed 
in the animal facility of the Department of Fundamental Neuroscience of the Université de 
Lausanne with 12:12 light/dark cycle with normal illumination, in groups of 5 per cage during one 
week for acclimatization prior to surgery. For experiments, mice were maintained anesthetized 
with isoflurane (1.5 – 2 % in nitrous oxide /oxygen 70 %/30 %) using a face mask. Body 
temperature was maintained at 37.0 ± 0.5°C throughout surgery (FHC Inc., Bowdoinham, ME, 
USA). Regional cerebral blood flow (rCBF) was measured and continuously recorded throughout 
the operation in all animals by laser-Doppler flowmetry (Perimed) with a flexible probe fixed on 
the skull (1 mm posterior and 6 mm lateral from bregma). Transient focal cerebral ischemia (30 
min or 45 min depending on the set of experiments) was induced by occlusion of the left MCA 
with an intra-arterial suture as described elsewhere (11). Briefly, the left common carotid artery 
and the left external carotid artery were exposed and ligated following a ventral midline neck 
incision. Ischemia was induced by inserting a silicon-coated nylon monofilament (0.17 mm 
diameter) through the left common carotid artery into the internal carotid artery until mild 
resistance was felt and a drop to less than 20 % of initial rCBF was registered. rCBF was monitored 
and maintained below 20 % of the baseline level during ischemia. Reperfusion was considered 
successful if the rCBF rose above 50 % of baseline. Only mice that had a drop of 80% of rCBF and 
accomplished a reperfusion of above 50% of baseline in the rCBF were included in the study. They 
received five microliters per gram of body weight of either sodium D-lactate solution (200 mM), 
pyruvate solution (200 mM) or vehicle solution (PBS) injected randomly in the tail vein at 
reperfusion using a 1 ml syringe with a 25-gauge needle and a mouse restrainer (Braintree 
Scientific Inc., Braintree, Mass., USA). All surgeries were performed during day-light, between 9am 
and 5pm. The surgeon was not blinded. Each mouse was considered as an experimental unit. 
At the beginning of the surgery, mice were administered 0.025 mg/kg of buprenorphine 
subcutaneously for post-surgery analgesia. Once the animals were awake, they were housed 
overnight in an incubator at 28°C.  
Behavioral evaluation 
The neurologic deficit was evaluated after reperfusion and before euthanasia, with a composite 
neuroscore graded for severity after surgery (0: no observable neurologic deficit; 1: failure to 
extend the right forepaw; 2: circling to the contralateral side, and 3: loss of walking or righting 
reflex) as previously described (11) and motor performance assessed on the Rotarod treadmill 
(UgoBasile, Milan, Italy). In this test, mice were placed on the rotating cylinder, set to accelerate 
uniformly from 4 to 40 r.p.m., and their latency to fall was recorded before 600 seconds. The 
animals were trained on 2 different days before surgery, with two trials in each training session. 
The test was then performed 24 and 48 h after MCAO, with two consecutive trials for each animal. 
The better of the two trials was selected. Points were attributed on the basis of performances 
expressed as a percentage of the best performance before ischemia (0: 90% to 100% and then 0.5 
point for each decrease of 15% until a maximum of 5 points for the highest neurological deficit). 
The behavior evaluation was assessed in a blinded manner.  
Determination of ischemic lesion volumes 
Animals were sacrificed 48 h after the onset of focal ischemia and 20-µm-thick, 720-µm-distant, 
coronal cryostat sections were stained with cresyl violet for histologic determination of lesion size. 
Digitalized images of the Nissl-stained tissue were acquired under a light stereomicroscope (Leica 
MZ16FA) and the lesion area was measured using ImageJ software. Infarct volume was calculated 
by multiplying the sum of the lesion areas on each section by the distance between sections (13). 
Immunohistochemistry 
Mice were injected intraperitoneally with a lethal dose of pentobarbital (10mL/kg, Sigma, 
Switzerland) and then perfused with 150mL of 4% paraformaldehyde (Sigma-Aldrich, USA) 
dissolved in 1 x PBS at pH 7.4. Brains were dissected, postfixed overnight at 4°C, cryoprotected 24h 
in 30% sucrose solution (Sigma-Aldrich, USA) and rapidly frozen. Twenty µm thick coronal 
microtome-cryostat (leica MC 3050S) sections were stored in cryoprotectant (30% ethylene glycol 
and 25% glycerin in 1 x PBS) at -20°C. For immunostaining, sections were washed three times in 1 x 
PBS and blocking of non-specific binding was achieved by incubating in 1 x PBS containing 1% 
bovine serum album, 0.1% Triton X-100 and 10% normal goat serum during 1h. Double labeling 
was carried out overnight at 4°C in the 1 x PBS solution without normal goat serum and different 
antibodies: monoclonal mouse anti-neuronal nuclear antigen (NeuN) antibody (1:500 dilution, 
Sigma) or monoclonal mouse anti-microtubule associated protein (MAP2) antibody (1:300 dilution, 
Sigma) and polyclonal rabbit anti-hydroxycarboxylic acid receptor (HCA1) (1:500 dilution; Sigma). 
After washing three times with 1 x PBS, brain sections were incubated for 2h at room temperature 
with the following fluorescent secondary antibodies: donkey anti-rabbit Alexa-594 (1:250, 
Invitrogen), donkey anti-mouse Alexa-488 (1:250, Invitrogen) for 2h at room temperature. After 
immunostaining brain sections were incubated for 10 min with 4,6 diamidino-2-phenylindole 
(DAPI) (Sigma, Buchs, Switzerland) dissolved in 1 x PBS (1/100,000) to reveal nuclei. Preparations 
were then maintained at 4°C until observation with a Zeiss LSM 710 Quasar Confocal Microscope 
(Zeiss, Feldbach, Switzerland).´ 
 
 
Western blotting 
For protein expression experiments, young adult male mice were subjected to 30 minutes MCAO 
as described above and sacrificed either at 1h, 3h, 8h, 24 h or 48h after reperfusion. Striatum 
(caudate and putamen), primary motor and somatosensory cortex as well as hippocampus were 
collected using a rodent brain matrix (adult mouse, coronal sections, ASI Instruments, MI, USA). 
Total proteins were extracted from brain tissues by cellular lysis in ice-cold RIPA buffer (#9806, Cell 
Signaling, Beverly, MA, USA) supplemented with a mixture of protease inhibitors (Complete 
11257000; Roche, Basel, Switzerland). Protein quantification was performed with the Pierce BCA 
Protein Assay kit (#23227, Thermo Fisher Scientific, Pierce, Lausanne, Switzerland) and about 20 
μg of proteins were denatured (95 °C) for 5 minutes in SDS-PAGE sample buffer (60 mM Tris-HCl 
pH 6.8, 5 % SDS, 6.6 % glycerol, 5 mM EDTA, 5 % β-mercaptoethanol and 0.1 % bromophenol 
blue). Samples were separated on a 10 % acrylamide gel with a 4 % stacking gel using an 
Electrophoresis Unit (Bio-Rad, Cressier, Switzerland). Proteins were then electroblotted onto 
nitrocellulose membranes (0.45 µm; #162-0115, Bio-Rad, Cressier, Switzerland) using the 
Electrophoresis Unit. Nonspecific binding sites were blocked for 1 hour at room temperature with 
a solution of Tris-Buffered-Saline (TBS-T; 50 mM Tris-HCl pH 7.5, 150mM NaCl) supplemented with 
0.1 % Tween-20 and containing 10 % (wt/vol) skimmed milk. Blots were then incubated overnight 
at 4°C with specific primary antibodies in TBS-T 0.1 % containing 1 % skimmed milk: rabbit anti-
mouse GPR81-S296 (HCA1) (1:500 dilution; #SAB1300790, Sigma, Buchs, Switzerland). Blots were 
washed three times in TBS-T 0.1% and subsequently incubated 2 h at room temperature with 
horseradish peroxidase-conjugated donkey anti-rabbit IgG (#NA9340V, 1:10.000 dilution; GE 
Healthcare, Glattbrugg, Switzerland). After being washed three times in TBS-T 0.1 %, blots were 
processed using Immun-StarTMWesternCTM Chemiluminescent Kit (#170-5070, Bio-Rad, Cressier, 
Switzerland). Chemiluminescence detection was performed with the ChemiDoc™ XRS System 
(#170-8070, Bio-Rad, Cressier, Switzerland). Total protein content assay was performed with the 
Pierce Reversible Protein Stain kit (#24580, Thermo Fisher Scientific, Pierce, Lausanne, 
Switzerland) and revealed with the ChemiDoc™ XRS System (#170-8070, Bio-Rad, Cressier, 
Switzerland). Both types of labeling were quantified with the ImageLab 3.0 software (Bio-Rad, 
Cressier, Switzerland) and the HCA1 (GPR81) protein expression was normalized to the total 
protein content. 
Organotypic hippocampal slice cultures 
Hippocampal slice cultures were prepared as described elsewhere (Berthet et al., 2009) from P8 to 
P10 rats (OFA Sprague Dawley, Janvier, France). Coronal hippocampal sections (350µm) were 
cultured on sterile porous membrane units (Millicell, Millipore, Billerica, MA, USA) in wells 
containing 1mL of culture medium with D-glucose 36 mM, 25% horse serum, 50% MEM (minimal 
essential medium supplemented with HEPES and sodium bicarbonate; Gibco), 25% HBSS (Hank’s 
balanced salt solution; Gibco), and L-glutamine 2 mM (Sigma-Aldrich, St. Louis, MO, USA). Cultures 
were kept at 33°C, 5% CO2, 100% humidity for 4 days. The medium was replaced by fresh identical 
medium at day 4, and then by culture medium with 15% horse serum, 60% MEM, 25% HBSS, and 
L-glutamine 2 mM at day 7 and 10. Experiments were conducted after 10 days of culture. 
Oxygen and glucose deprivation on organotypic hippocampal slice cultures  
Oxygen and glucose deprivation (OGD) experiments were performed in serum-free low glucose 
medium, DMEM (Dulbecco’s modified Eagle’s medium; D5030, Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with D-glucose 1 mM and L-glutamine 2 mM and equilibrated for 1 h at 37 °C, in a 
humidified hypoxic chamber (COY,MI,USA) with an atmosphere of 5 % O2, 5 % CO2, completed by 
N2. Hippocampal slices were transferred into this medium and placed into the hypoxic chamber for 
1 h. Control cultures were kept in 60 % MEM, 15 % horse serum, 25 % HBSS, and L-glutamine 2 
mM for 1 h at 37 °C in a humid normoxic atmosphere (11, 14). For recovery, cultures where then 
transferred into fresh culture medium at 33 °C for 48 h. Cultures were randomly treated with 
either D-lactate, pyruvate, acetate (Sigma-Aldrich, St. Louis, MO, USA, diluted in 1 x phosphate-
buffered saline, PBS, pH 7), 3,5-dihydroxybenzoic acid (3,5-DHBA, Sigma-Aldrich, St. Louis, MO, 
USA, diluted in ethanol) or an equal volume of culture medium. Sodium D-lactate at a final 
concentration of 4 mM, pyruvate at 10 mM, sodium acetate at 0.13, 0.2, 4 or 8 mM or 3,5-DHBA at 
4 mM was administered immediately after OGD.  
Assessment of cell death in hippocampal slices 
Cell death was determined in the CA1 region using the fluorescent viability indicator propidium 
iodide (PI). PI was applied in each dish (50 µg/mL) 1 h before measurement. PI fluorescence 
emission (excitation wavelength 536nm, emission wavelength 617nm) was measured 48 hours 
after hypoxia using an epifluorescence microscope with a 5x lens coupled to a camera (Leica). PI 
images were acquired with standardized camera settings and signal intensity was measured with 
ImageJ software (ImageJ 1.36b, National Institute of Health). After subtracting the background 
fluorescence on each slice, the results were expressed as a percentage of maximal cell death 
obtained by submerging slices in PBS for 24 h at 4°C. Cell death was averaged for the 4 slices of 
each culture well. The experimenter was not blinded. 
Experiments using 
11
C-D-lactate in Sprague Dawley rats 
Radiotracer: The D- and L-enantiomers of 1-
11
C-lactic acid were produced by a previously 
described radiosynthetic method, which includes separation of racemic 1-
11
C-lactic acid by 
preparative chiral ligand exchange HPLC. Prior to use, the fractions corresponding to 1-
11
C-D- or 1-
11
C-L-lactic acid were further purified and finally formulated as sodium salts in physiologically 
acceptable sodium phosphate buffered saline (pH 7). The chemical and enantiomeric purity of 
each isolated radiolabeled enantiomer was routinely monitored by analytical chiral ligand 
exchange HPLC as part of the radiosynthesis quality control and typically revealed over 99% 
enantiomeric excess of the final product. The specific activity at the end of the synthesis was 
about 400 GBq/µmol. Both preparative and analytical chiral ligand exchange chromatography 
were performed on reversed-phase C18 columns (ODS), coated with a D- or L-penicillamine derived 
chiral selector. The preparation of the chiral selectors, the coating procedures for the HPLC 
columns and the HPLC separation conditions have been described in detail earlier (15). 
  
Surgical preparation: Surgery was performed under isoflurane anesthesia (2 – 3 % in air/oxygen 70 
%/30 %) and involved the placement of an arteriovenous shunt (av-shunt) from the right femoral 
artery to the right femoral vein, tracheotomy for mechanical ventilation and craniotomy for the 
placement of the beta scintillator. The actual experiments were performed under α-chloralose 
anesthesia (44 mg/kg s.c.). The av-shunt was run through a coincidence scintillator (GE Medical 
Systems). The online arterial sampling procedure is described in detail elsewhere (16). In short, 
total radioactivity in arterial blood was continuously recorded and was then corrected for i) a 
different tracer concentration in whole blood and plasma and ii) the build-up of labeled 
metabolites. 
D-lactate kinetics in the somatosensory cortex: For the measurement of the time-course of 1-
11
C-
D-lactate in the brain, an intracortical beta probe was used (17, 18). Twenty minutes of data were 
acquired at baseline condition after injection of 200-300 MBq of radiotracer in 5 animals. In one of 
these animals baseline cerebral blood flow was determined prior to 1-
11
C-D-lactate acquisition 
using 
15
O-H2O and the methodology described previously (17). The first pass extraction fraction of 
1-
11
C-D-lactate was then calculated using the relationship EF = K1/CBF where K1 is the transport 
parameter describing (1-
11
C-D-lactate) transport from blood to tissue (figure 2a). 
Kinetic modeling: Acquired radioactivity data was analyzed using the software package PMOD 
(PMOD Technologies GmbH, Zürich, Switzerland). The investigated methods consisted of standard 
compartmental modeling using the arterial input function and the one-tissue compartment model. 
The parameters are as follows: K1 describes the transport of the tracer across the blood brain 
barrier and k2 represents the back-diffusion of label from tissue to the blood system. Carbon is 
labeled as “C”. Label exchange between compartments is described by the following differential 
equation: 


= 	
 −	 
The basis of the calculation of the CBF measurement was also the one-tissue compartment model 
including a partition coefficient for 
15
O-H2O [for details see (17)].  
Metabolite analysis in the blood: Samples (about 400 μL) were collected at different time points 
after tracer injection, with a maximum of 4-5 blood samples per animal, to determine the time-
course of the ratio of the 
11
C activity in plasma to whole blood and for analysis of authentic tracer 
and metabolites. These samples were first centrifuged for 3 minutes at 2000 rpm. Proteins were 
then precipitated with 75 μL acetonitrile in 50 μL plasma. After centrifugation for 3 minutes at 
2000 rpm, the composition of the 
11
C-derived radioactivity in the supernatant (80 µL) was analyzed 
by high-performance liquid chromatography (HPLC) on a polymeric column (PRP-1, 5-µm, 250 × 
4.1 mm i.d., Hamilton, U.S.A.) with 3 mmol/L phosphoric acid in water (pH 2.67) as the mobile 
phase (1 mL/min). The retention times of 
11
C-HCO3
−
  (3.3 min) and lactic acid (5.1 min) were 
determined by using aqueous solution of NaHCO3 and DL-lactic acid as reference compounds, 
detected by UV absorption at 220 nm. The amount of authentic tracer was expressed as a fraction 
of total plasma counts.  
Metabolite analysis in brain: At the end of the experiment the rats were perfused with PBS, brains 
were removed and prepared for measurements with the HPLC system. Each brain was first 
homogenized before adding acetonitrile (150 %, i.e. 1.5x volume / weight of brain sample). The 
subsequent procedure was the same as with the blood samples described above, except that the 
amount of supernatant injected into the HPLC system was 200 µL. 
 
Statistical analysis. 
All data are presented as mean ± s.d. Statistical analyses were performed using non-parametric 
tests; one way ANOVA (Kruskal Wallis followed by Dunn’s multiple comparison test) was used for 
analysis of in vitro experiments and the Mann-Whitney test was used for comparison between two 
groups in the in vivo experiments and for the behavioral experiments. Paired t-test was used to 
compare protein expression. P < 0.05 was considered statistically significant. 
Results 
HCA1 receptor expression and a possible neuroprotective role in ischemia 
Recent studies revealed the presence and mechanism of action of the HCA1 receptor 
(formerly known as GPR81) in the central nervous system (8-10). Since L-lactate acts as an 
endogenous ligand for this receptor, it was of interest to describe the cellular expression of this 
receptor in several brain regions affected by ischemic damage in the mouse tMCAO model. We 
confirmed a strong neuronal expression of the HCA1 receptor in the hippocampus (CA1 and 
dentate gyrus), the cortex and the striatum as revealed by double labeling immunofluorescence 
for the HCA1 receptor and the neuronal markers NeuN or MAP2 (figure 1: NeuN [green], MAP2 
[green], HCA1 [red], DAPI [blue]). The next step was to evaluate whether such HCA1 receptor 
expression was altered at different time points following 30 minutes tMCAO. For this purpose, the 
level of HCA1 receptor expression was evaluated on Western blots in protein extracts from 
hippocampus, cerebral cortex and striatum at 1, 3, 8, 24 and 48 hours following 30 minutes of 
tMCAO. Results at 1, 3 and 8 hours did not reveal significant differences between the three brain 
structures investigated (see supplemental table 1). However, a significant increase in HCA1 
receptor expression was seen in the ischemic cortex after 24 hours (1.2 ± 0.2, p < 0.05 vs. 
contralateral cortex; figure 2a). Even though there is neuronal loss in the lesion core (ischemic 
striatum), we did not observe a significant decrease in HCA1 receptor expression in this structure 
(0.8 ± 0.3, n.s. vs. contralateral cortex) which might reflect a compensatory increase in HCA1 
receptor expression in remaining neurons (figure 2a). At 48 hours post-ischemia, no difference 
could be observed between ischemic and contralateral tissues (see supplemental table 1). Based 
on this result and the possibility that lactate regulates HCA1 receptor expression we injected L-
lactate intravenously at the beginning of the reperfusion period and monitored any changes in 
HCA1 receptor expression at 24 hours after the ischemic episode. We found an increase in HCA1 
receptor expression in both the ischemic cortex (1.57 ± 0.34, p < 0.04 vs. contralateral cortex) and 
ischemic striatum (1.7 ± 0.4, p < 0.05 vs. contralateral striatum) while no significant difference was 
observed for the hippocampus (figure 2b). These observations suggest that the expression of the 
HCA1 receptor may be modulated by ischemia and potentially by lactate injected at reperfusion. 
We went on to further investigate the role of HCA1 receptors under ischemic conditions in 
an in vitro model. For this purpose, we used rat organotypic hippocampal slices exposed to an 
oxygen-glucose deprivation (OGD) protocol. We observed a significant increase in HCA1 receptor 
expression 48 hours after OGD (1.45 ± 0.16, p < 0.01 vs. control slices; figure 2c). In order to 
determine if the enhanced HCA1 receptor expression could play a role in the neuroprotective 
effect of L-lactate in this model, organotypic hippocampal slices were exposed to the HCA1 
receptor agonist 3,5-dihydroxybenzoic acid (DHBA) after OGD. Results show that DHBA produced 
significant protection as it reduced neuronal cell death in the CA1 region of the hippocampus 48 
hours after insult from 13.5 ± 7.2 % to 7.4 ± 5.2 % (p < 0.05; figure 2d). 
D-Lactate neuroprotection in ischemia models 
The D enantiomer of lactate has been described to act at least as a partial agonist of the 
HCA1 receptor (9, 19). For this reason, we tested the neuroprotective effect of D-lactate both in 
vitro and in vivo. The administration of 4 mM D-lactate to rat organotypic hippocampal slices 
directly after OGD also resulted in significantly reduced neuronal cell death in the CA1 region of 
the hippocampus 48 hours after OGD, from 29.2 ± 14.3 % to 11.3 ± 7.3 % (p < 0.05; figure 3a). It is 
noteworthy that the neuroprotective effect approaches that previously reported for L-lactate in 
this model (11). We then tested D-lactate in vivo by intravenous administration of 1 µmol/g D-
Lactate after 45 minutes tMCAO. Mice with satisfactory ischemia (rCBF < 20% of baseline) and 
reperfusion (rCBF above 50% of baseline) received a single intravenous administration of D-lactate 
or vehicle, 10-15 minutes after the silicon-coated monofilament was removed allowing 
reperfusion. A total of 9 mice were not included in the study as they did not fulfill the rCBF 
inclusion criteria. Single administration of D-lactate significantly decreased the infarct volume from 
81.8 ± 40.1 mm
3
 (control group) to 45.5 ± 32 mm
3
 (D-lactate group) measured 48 hours after 
ischemia (p < 0.05; figure 3b). Again, the magnitude of neuroprotection was comparable to that 
reported previously for L-lactate in vivo (12). Behavioral performances on motor task assessment 
showed a clearly milder neurological deficit at 48 hours (p < 0.05) in the D-Lactate group, from a 
median of 2.5, with scores ranging from 1 to 5 (control group), to a median of 1, with scores 
ranging from 0 and 1 (D-lactate group, p < 0.05, figure 3c). One mouse from the control group and 
two mice from the D-lactate group died during the first night after surgery. Three mice per group 
were sacrificed within the first 6 hours after surgery due to the presence of repeated seizures as 
required by the veterinary authority. 
Cerebral D-lactate metabolism 
Different in vivo and in vitro studies have suggested that D-lactate is not metabolized in 
cerebral tissue (6, 20, 21) based on the apparent lack of expression of the specific enzyme D-
lactate dehydrogenase in mammals. In order to clarify this issue in the rodent brain we set up a 
series of experiments using radiolabeled D-lactate to trace its metabolism and kinetics (figure 4a). 
To evaluate the brain uptake of D-lactate, we determined the first pass extraction fraction, which 
was 16 %. The tissue kinetics of 1-
11
C-D-lactate displayed an increase over 5 minutes and slow 
washout thereafter upon tracer injection (figure 4b). The average respective first-order kinetic rate 
constants obtained by kinetic modeling were 0.059 ± 0.01 ml/min/ml tissue (K1) and 0.063 ± 0.01 
min
-1
 (k2). Average lactate levels in the blood were 2.2 ± 0.93 mmol/L. 
11
C-CO2 turned out to be the only metabolite in blood and brain. The time course of the 
fraction of authentic tracer in arterial plasma is shown in figure 4c. The pooled fraction data of all 
animals was approximated by a fit of a quadratic polynomial. This function was subsequently 
employed to convert the total plasma activity to the time-course of authentic 
11
C-lactate (= input 
curve).  At 40 minutes the fraction of true tracer in plasma dropped to about 30 percent. 
Measurements in brain tissue at the end of the experiment revealed about one third CO2 and two 
thirds lactate (figure 4d).  
Effect of pyruvate and acetate in ischemia models 
Results obtained on D-lactate metabolism suggest that in addition to a possible activation 
of the HCA1 receptor, utilization of D-lactate as an energy substrate might also contribute to its 
beneficial effect in ischemia. Therefore, we explored the specificity of its metabolic mode of action 
by testing the neuroprotective effect of two other monocarboxylates. Pyruvate is the immediate 
downstream product of either L- or D-lactate and is the main substrate entering the Krebs cycle to 
provide energy. Other groups have previously described the neuroprotective effect of pyruvate in 
different models of cerebral ischemia (2, 22). In agreement with these observations, 
administration of 10 mM pyruvate directly after OGD significantly decreased cell death in the 
hippocampal CA1 region at 48 h from 25.4 ± 14.5% to 13.9 ± 10.3% (p < 0.05; figure 5a and 5b). In 
contrast, we did not observe a significant benefit in vivo after tMCAO. In our hands pyruvate 
administration at reperfusion after 30 minutes tMCAO induced only a slight reduction in lesion size 
(p = 0.4), from 91.9 ± 53.6 mm3 (control group, n= 7) to 64.6 ± 53.4 mm3 (pyruvate, n=5) 48 hours 
after ischemia. A total of 4 mice were not included because they did not fulfill rCBF inclusion 
criteria. There was no mortality in this experiment. Due to the inherent variability of the model our 
experiment was however not powered to detect a significant neuroprotective effect (the sample 
size calculation using an alpha error of 5% and a beta error of 50% resulted in a sample size of 21 
per group, www.dssresearch.com). 
As both L- and D-lactate could be taken up and metabolized in principle by either neurons 
or astrocytes, we wanted to determine whether the beneficial metabolic effect of lactate in vitro 
could be exerted via its use by astrocytes. For this purpose, we made use of acetate which is 
known to be specifically taken up and used as energy substrate by astrocytes (23). However, the 
addition of different concentrations of acetate (0.13, 0.2, 4 and 8 mM) to organotypic 
hippocampal slices 1 hour after OGD did not provide significant neuroprotection (figure 5a and 
5c).  
Discussion 
After being considered for decades as a waste-product of metabolism lactate has been 
shown to be able to support synaptic activity (1, 24) and is nowadays recognized as a prominent 
energy substrate in the central nervous system (25). Lactate is produced under physiological 
conditions (26, 27) and it is suggested to play an important role in the metabolic support of long 
axons (6, 28) as well as in long-term memory formation (29). Lack of adequate lactate supply has 
also been implicated in some neurodegenerative diseases such as amyotrophic lateral sclerosis 
(30). Moreover, exogenous lactate supplementation seems beneficial after traumatic brain injury 
(31-33). In ischemic conditions, our group and others have demonstrated neuroprotection 
following L-lactate administration at reperfusion after tMCAO (11, 12, 34). Similarly, brain lactate 
was found to be essential to improve post ischemic outcome after cardiac arrest (35). Lactate can 
be transported from one cell type to another by monocarboxylate transporters that are selectively 
expressed in different cell types and which can transport monocarboxylates with different 
affinities [for a comprehensive review please refer to (36)]. More recently, lactate has been 
described to act as a signaling molecule in the central nervous system, either through the  HCA1 
receptor (8, 9) or through an unknown receptor yet to be specified (37). 
Our initial characterization of the distribution of the HCA1 receptor in three brain regions 
affected following tMCAO confirmed a prominent neuronal expression in the central nervous 
system (8, 9). Interestingly, our data also suggested that the cerebral expression of HCA1 can be 
modulated under certain conditions. Lactate itself seems to be a signal for the induction of its own 
receptor. However, whether lactate accumulation following ischemia is responsible for the 
enhancement of the HCA1 receptor observed after 24 hours of reperfusion remains to be directly 
demonstrated. Nonetheless our results provide the first evidence that activation of HCA1 
receptors alone is sufficient to provide neuroprotection, at least in an in vitro ischemic model. Our 
demonstration that neuroprotection was also achieved with D-Lactate confirms this observation in 
that D-lactate was shown to exhibit at least partial agonist activity on HCA1/GPR81 receptor (19, 
38) and that D-lactate was considered as a non-metabolizable lactate enantiomer and often used 
as a negative control to demonstrate the necessity of L-lactate use as an alternative energy 
substrate. However unexpectedly, we found that D-lactate is extracted by the rodent brain and 
oxidized. In fact, one third of D-lactate was metabolized to CO2 which is only marginally less than 
the previously reported fraction of CO2 produced from L-lactate [42 ± 8 % CO2 after 40 minutes; 
(1)]. This observation suggests that the rodent brain might possess a D-Lactate dehydrogenase 
activity. In accordance, the isolation of human and mouse transcripts encoding a homolog of the 
yeast D-lactate dehydrogenase was reported and its expression was found in various tissues, 
including the brain (39). However, it remains to be determined whether the presence of a cerebral 
D-Lactate dehydrogenase enzyme is sufficient to explain our results or if the activity is carried out 
by another a priori unrelated enzyme. 
In the central nervous system, pyruvate is transported mainly by MCT1 and MCT2 in the 
direction of the concentration gradient and these MCTs are located in astrocytes and neurons, 
respectively (4, 40). Possible explanations for the neuroprotection against ischemic damage 
induced by either L- or D-lactate are the fact that lactate is converted to pyruvate by the 
mitochondrial lactate dehydrogenase (mLDH) to fuel the Krebs cycle and therefore used as 
energetic substrate and that this conversion produces reduced nicotinamide adenine dinucleotide 
(NADH) that will in turn act as a reactive oxygen species (ROS) scavenger (41). Evidence pointing 
towards this metabolic explanation is the protection exerted by the administration of 10 mM 
pyruvate in vitro. Protection is not seen in vivo though. However, in support of a metabolism-
mediated neuroprotective effect others (2, 22) have shown protection in vivo using an extended 
i.v. mode of administration of pyruvate (22). This difference in the mode of administration might 
explain the different in vivo results, although we cannot exclude that lactate might prove to be a 
more efficient neuroprotective agent, notably in vivo, in particular due to the ability of both L- and 
D-lactate to activate the HCA1 receptor. 
It has been shown that acetate is preferentially transported by MCT1 and metabolized in 
astrocytes (18, 23). During ischemia it was observed that 
14
C-acetate uptake is decreased as early 
as 3 minutes after the onset of ischemia. The degree of reduction in 
14
C-acetate uptake correlates 
with the severity of ischemia which, according to Hosoi et al., relates to the depression of glial 
metabolism (42). Even though the reduction in 
14
C-acetate uptake was reversible and reached full 
recovery 3 hours after 30 minutes MCAO reperfusion, Hosoi et al. did not evaluate the functional 
outcome of acetate administration. We showed here that the administration of acetate did not 
exert protection against neuronal death in hippocampal slices subjected to oxygen and glucose 
deprivation. Even though there is an increased energy demand in neurons and astrocytes 
subjected to ischemic insult, this result suggests that energy supply to astrocytes is not enough to 
exert neuroprotection. It should be noted that using an in vitro assay of ligand-induced 
35
S-GTPγS 
binding with membranes from CHO cells expressing human HCA1 receptor, Cai et al., described 
that neither sodium pyruvate nor sodium acetate showed binding activity (19). As neither acetate 
nor pyruvate bind to the HCA-1 receptor, the results shown here cannot be related to HCA1 
signaling pointing to the use of pyruvate and acetate as metabolic substrates. 
 Some limitations to consider in the present study are that (a) our in vivo stroke model 
involves a transient occlusion with removal of the silicon filament, therefore our results are limited 
to be translated to patients with either a spontaneous reperfusion or successful intravenous 
thrombolysis or intrarterial recanalisation. Evaluating the effect of lactate administration in 
permanent ischemia is an important step before aiming for translation in clinical practice. (b) 
Ischemia is induced under isoflurane anesthesia and this compound has been described as 
neuroprotective by itself. Therefore, we might not be observing the neurological damage to its 
fullness. In our in vitro model, oxygen and glucose deprivation on organotypic hippocampal slice 
cultures, the tissue architecture is only partially preserved and while some neuronal connections 
are maintained many are interrupted. Furthermore, there is no blood circulation. Despite these 
limitations, both models complement each other and strengthen our observations. (c) It should be 
considered as well that lactate was shown to increase regional CBF in physiologically activated but 
not resting human brain (43). Although we cannot rule out a contribution from CBF changes, the 
effect observed in the in vitro model, independently from blood flow, shows that lactate exerts a 
neuroprotective effect independently from possible effects on cerebral blood flow. 
Taken together, these data point to the possibility that lactate, independently of the 
enantiomer type, may confer neuroprotection following ischemia by two distinct mechanisms: 
One, through the classical metabolic pathway providing an alternative energy supply to deprived 
neurons and the other through a receptor-mediated signal transduction mechanism in neurons. In 
both cases the exact targets within the cell still need to be identified. 
Supplementary material is available at the JCBFM web site (www.nature.com/jcbfm). 
 
Acknowledgments: This work was supported by a CONACYT fellowship to XC and a grant from the 
Biaggi Foundation to LH. The authors thank Maité Willaredt for her help with behavioral 
evaluation, Carole Berthet for her preliminary observation on the role of D-lactate in ischemia and 
Melanie Price for critically reading the manuscript. 
Disclosure of Interests/Conflicts statement: Authors have no conflict of interest 
 
References 
1. Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B. In vivo evidence for lactate as a 
neuronal energy source. J Neurosci. 2011;31(20):7477-85. 
2. Lee JY, Kim YH, Koh JY. Protection by pyruvate against transient forebrain ischemia in rats. 
J Neurosci. 2001;21(20):RC171. 
3. Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Muller-Fielitz H, et al. The beta-
hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nature 
communications. 2014;5:3944. 
4. Pellerin L, Bergersen LH, Halestrap AP, Pierre K. Cellular and subcellular distribution of 
monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res. 
2005;79(1-2):55-64. 
5. Moreira TJ, Pierre K, Maekawa F, Repond C, Cebere A, Liljequist S, et al. Enhanced cerebral 
expression of MCT1 and MCT2 in a rat ischemia model occurs in activated microglial cells. J Cereb 
Blood Flow Metab. 2009;29(7):1273-83. 
6. Rinholm JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, Attwell D. Regulation 
of oligodendrocyte development and myelination by glucose and lactate. J Neurosci. 
2011;31(2):538-48. 
7. Rooney K, Trayhurn P. Lactate and the GPR81 receptor in metabolic regulation: 
implications for adipose tissue function and fatty acid utilisation by muscle during exercise. The 
British journal of nutrition. 2011;106(9):1310-6. 
8. Lauritzen KH, Morland C, Puchades M, Holm-Hansen S, Hagelin EM, Lauritzen F, et al. 
Lactate receptor sites link neurotransmission, neurovascular coupling, and brain energy 
metabolism. Cerebral cortex. 2014;24(10):2784-95. 
9. Bozzo L, Puyal J, Chatton JY. Lactate modulates the activity of primary cortical neurons 
through a receptor-mediated pathway. PloS one. 2013;8(8):e71721. 
10. Mariga ST, Kolko M, Gjedde A, Bergersen LH. Lactate transport and receptor actions in 
cerebral malaria. Frontiers in neuroscience. 2014;8:125. 
11. Berthet C, Lei H, Thevenet J, Gruetter R, Magistretti PJ, Hirt L. Neuroprotective role of 
lactate after cerebral ischemia. J Cereb Blood Flow Metab. 2009;29(11):1780-9. 
12. Berthet C, Castillo Tovar X, Magistretti PJ, Hirt L. New Evidence of Neuroprotection by 
Lactate after Transient Focal Cerebral Ischaemia: Extended Benefit after Intracerebroventricular 
Injection and Efficacy of Intravenous Administration. Cerebrovasc Dis. 2012;34(5-6):329-35. 
13. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated 
method for measuring brain infarct volume. JCerebBlood Flow Metab. 1990;10(2):290-3. 
14. Badaut J, Hirt L, Price M, de Castro Ribeiro M, Magistretti PJ, Regli L. 
Hypoxia/hypoglycemia preconditioning prevents the loss of functional electrical activity in 
organotypic slice cultures. Brain Res. 2005;1051(1-2):117-22. 
15. Drandarov K, Schubiger PA, Westera G. Automated no-carrier-added synthesis of [1-11C]-
labeled D- and L-enantiomers of lactic acid. Applied radiation and isotopes : including data, 
instrumentation and methods for use in agriculture, industry and medicine. 2006;64(12):1613-22. 
16. Weber B, Burger C, Biro P, Buck A. A femoral arteriovenous shunt facilitates arterial whole 
blood sampling in animals. European journal of nuclear medicine and molecular imaging. 
2002;29(3):319-23. 
17. Weber B, Spath N, Wyss M, Wild D, Burger C, Stanley R, et al. Quantitative cerebral blood 
flow measurements in the rat using a beta-probe and H2 15O. J Cereb Blood Flow Metab. 
2003;23(12):1455-60. 
18. Wyss MT, Weber B, Treyer V, Heer S, Pellerin L, Magistretti PJ, et al. Stimulation-induced 
increases of astrocytic oxidative metabolism in rats and humans investigated with 1-11C-acetate. J 
Cereb Blood Flow Metab. 2009;29(1):44-56. 
19. Cai TQ, Ren N, Jin L, Cheng K, Kash S, Chen R, et al. Role of GPR81 in lactate-mediated 
reduction of adipose lipolysis. Biochemical and biophysical research communications. 
2008;377(3):987-91. 
20. Borg MA, Tamborlane WV, Shulman GI, Sherwin RS. Local lactate perfusion of the 
ventromedial hypothalamus suppresses hypoglycemic counterregulation. Diabetes. 
2003;52(3):663-6. 
21. Tekkok SB, Brown AM, Westenbroek R, Pellerin L, Ransom BR. Transfer of glycogen-
derived lactate from astrocytes to axons via specific monocarboxylate transporters supports 
mouse optic nerve activity. J Neurosci Res. 2005;81(5):644-52. 
22. Ryou MG, Liu R, Ren M, Sun J, Mallet RT, Yang SH. Pyruvate protects the brain against 
ischemia-reperfusion injury by activating the erythropoietin signaling pathway. Stroke. 
2012;43(4):1101-7. 
23. Waniewski RA, Martin DL. Preferential utilization of acetate by astrocytes is attributable to 
transport. J Neurosci. 1998;18(14):5225-33. 
24. Schurr A, West CA, Rigor BM. Lactate-supported synaptic function in the rat hippocampal 
slice preparation. Science. 1988;240(4857):1326-8. 
25. Bergersen LH. Lactate transport and signaling in the brain: potential therapeutic targets 
and roles in body-brain interaction. J Cereb Blood Flow Metab. 2015;35(2):176-85. 
26. Fellows LK, Boutelle MG, Fillenz M. Physiological stimulation increases nonoxidative 
glucose metabolism in the brain of the freely moving rat. J Neurochem. 1993;60(4):1258-63. 
27. Hu Y, Wilson GS. A temporary local energy pool coupled to neuronal activity: fluctuations 
of extracellular lactate levels in rat brain monitored with rapid-response enzyme-based sensor. J 
Neurochem. 1997;69(4):1484-90. 
28. Funfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic 
oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485(7399):517-21. 
29. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, et al. Astrocyte-
neuron lactate transport is required for long-term memory formation. Cell. 2011;144(5):810-23. 
30. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia 
metabolically support axons and contribute to neurodegeneration. Nature. 2012;487(7408):443-8. 
31. Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C, et al. Sodium lactate 
versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-
injured patients. Intensive care medicine. 2009;35(3):471-9. 
32. Ichai C, Payen JF, Orban JC, Quintard H, Roth H, Legrand R, et al. Half-molar sodium lactate 
infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a 
randomized controlled trial. Intensive care medicine. 2013;39(8):1413-22. 
33. Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, et al. Cerebral metabolic 
effects of exogenous lactate supplementation on the injured human brain. Intensive care 
medicine. 2014;40(3):412-21. 
34. Horn T, Klein J. Neuroprotective effects of lactate in brain ischemia: dependence on 
anesthetic drugs. Neurochemistry international. 2013;62(3):251-7. 
35. Schurr A, Payne RS, Miller JJ, Tseng MT. Preischemic hyperglycemia-aggravated damage: 
evidence that lactate utilization is beneficial and glucose-induced corticosterone release is 
detrimental. J Neurosci Res. 2001;66(5):782-9. 
36. Pierre K, Pellerin L. Monocarboxylate transporters in the central nervous system: 
distribution, regulation and function. J Neurochem. 2005;94(1):1-14. 
37. Tang F, Lane S, Korsak A, Paton JF, Gourine AV, Kasparov S, et al. Lactate-mediated glia-
neuronal signalling in the mammalian brain. Nature communications. 2014;5:3284. 
38. Liu C, Kuei C, Zhu J, Yu J, Zhang L, Shih A, et al. 3,5-Dihydroxybenzoic acid, a specific agonist 
for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. The Journal of pharmacology and 
experimental therapeutics. 2012;341(3):794-801. 
39. Flick MJ, Konieczny SF. Identification of putative mammalian D-lactate dehydrogenase 
enzymes. Biochemical and biophysical research communications. 2002;295(4):910-6. 
40. Pierre K, Magistretti PJ, Pellerin L. MCT2 is a major neuronal monocarboxylate transporter 
in the adult mouse brain. J Cereb Blood Flow Metab. 2002;22(5):586-95. 
41. Schurr A, Gozal E. Aerobic production and utilization of lactate satisfy increased energy 
demands upon neuronal activation in hippocampal slices and provide neuroprotection against 
oxidative stress. Frontiers in pharmacology. 2011;2:96. 
42. Hosoi R, Kashiwagi Y, Tokumura M, Abe K, Hatazawa J, Inoue O. Sensitive reduction in 14C-
acetate uptake in a short-term ischemic rat brain. Journal of stroke and cerebrovascular diseases : 
the official journal of National Stroke Association. 2007;16(2):77-81. 
43. Mintun MA, Vlassenko AG, Rundle MM, Raichle ME. Increased lactate/pyruvate ratio 
augments blood flow in physiologically activated human brain. Proc Natl Acad Sci U S A. 
2004;101(2):659-64. 
 
 
 
 
 
  
 
 
Figures and tables 
Figure 1. Confocal visualization of HCA1 receptor expression. Using two different antibodies 
against neuronal cells, we confirmed with immunohistochemistry the localization of the HCA1 
receptor is in neurons. The brain structures analyzed were hippocampus (CA1 [1a-1f] and Dentate 
Gyrus (DG) [2a-2f] regions) primary cortex [3a-3f] and Striatum [4a-4f]. Color code: NeuN [green, a 
and c], MAP2 [green, d and f], HCA1 [red, b-c and e-f], DAPI [blue]. Magnification: 40µm. 
Figure 2. The HCA1 receptor expression is promoted by ischemia and plays a role in the 
neuroprotective effect. (a) Western blot analysis showed an increase in the HCA1 receptor 
expression at 24 h after tMCAO in the region surrounding the lesion site (primary motor and 
somatosensory cortex), in comparison to the contralateral hemisphere. (b) Intravenous L-lactate 
injection prompted an increase also in the lesion site (striatum) at the same time point (*p < 0.05; 
paired t-test ischemic vs contralateral hemisphere). (c) Western blot analysis showed an increase 
in the HCA1 receptor expression at 48 h after OGD (**p < 0.01 paired t-test). (d) Administration of 
4 mM 3-5 DHBA, an HCA1 receptor agonist, attenuated cell death when administered directly to 
the medium after OGD (*p < 0.05, ***p < 0.001 One way ANOVA Kruskal-Wallis test followed by 
Dunn’s multiple comparison test). 
Figure 3. Neuroprotection by D-lactate. a) In vitro, administration of 4 mM D-lactate induced a 
significant reduction in cell death, assessed by PI staining, 48 h after treatment (*p < 0.05, One 
way ANOVA Kruskal-Wallis followed by Dunn’s multiple comparison test). In vivo, intravenous 
injection of 1 µmol/g D-lactate after 45 min tMCAO decreased total infarct volumes measured 48 
h after ischemia (b) and improved the neurological outcome (c), neurologic deficit scores from 0, 
no deficit – white, to 5 worst outcome – black; *p < 0.05 Mann-Whitney test, two-tailed p-value). 
Figure 4. D-lactate metabolism. a) Schematic of biochemical pathways involved in the degradation 
of lactate and the proposed interpretation of the rate constants K1 and k2 which are 
mathematically defined by the one-tissue compartment model used for 1-
11
C-D-lactate data 
analysis. b) Measured radioactivity concentration in the brain (open circles), model fit (black line) 
and arterial input curve (gray line). The inset displays the residuals of the fitting to the one-tissue 
compartment model. Equal distribution around the neutral line supports the adequacy of the 
applied model. c) Fraction of native radiolabeled lactate over 40 minutes after intravenous 
injection of 1-
11
C-D-lactate in the blood. The filled circles represent data points from individual 
measurements and the solid line is the corresponding fit. d) Percentage of identified metabolites 
in brain tissue after 40 minutes. 
Figure 5. Administration of pyruvate and acetate after OGD. (a) Administration of 10 mM 
pyruvate directly to the medium after 1 h OGD in rat organotypic hippocampal slices was able to 
protect against ischemic damage. (b) Administration of various doses of acetate did not protect 
against ischemic damage. Cell death was assessed by PI staining 48 h after treatment. (c) 
Representative images of PI staining among each group can be observed in panel (*p < 0.05; One 
way ANOVA Kruskal-Wallis test followed by Dunn’s multiple comparison test). 
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